Mesenchymal Stem Cells

While bone marrow‐derived mesenchymal stem cells (BM-MSCs) represent a highly utile cell type for cell transplantation therapy, the molecular network underlying BM-MSC proliferation remains poorly understood. Now, researchers led by Takeshi Teramura (Kindai University, Osaka, Japan) report TGFβ‐activated kinase (Tak1) as a critical regulator of BM-MSC proliferation.

To develop the next generation of cell‐delivery materials and methods, we must have a better understanding of the metabolic switches mesenchymal stem cells (MSCs) experience upon transplantation. By designing treatment strategies with cell metabolism in mind, we may improve survival and the overall therapeutic potential of MSCs.

A new review article from the laboratory of David S.

Research showing that Bmi1 overexpression exerts anti‐aging effects may permit the development of enhanced mesenchymal stem cell-based therapeutic approaches

Researchers hope that comparing mesenchymal stem cells from various sources will drive the development of an treatment for obesity‐related kidney injury

A new clinical trial assesses autologous bone marrow-derived mesenchymal stem cell therapy in twelve patients with moderate to severe knee osteoarthritis

The growing interest surrounding the therapeutic application of purified and concentrated regenerative factors secreted by mesenchymal stem cell (MSCs) has recently focused on exosomes, which are now understood to be critical active pharmaceutical ingredients of MSC‐based therapies.

A recent STEM CELLS Translational Medicine article from the lab of Robert Bowers (Emory University, Atlanta, Georgia, USA) ai

Previous studies from the labs of J.

The realization that mesenchymal stem cells (MSCs) play tissue supportive functions has prompted an increasing number of studies in a variety of clinical indications, thereby revealing additional challenges.